{"title":"溃疡性结肠炎的医学治疗","authors":"Sumona Bhattacharya MD , Raymond K. Cross MD, MS","doi":"10.1016/j.scrs.2022.100863","DOIUrl":null,"url":null,"abstract":"<div><p>Ulcerative colitis<span><span><span><span> is a chronic inflammatory condition characterized by abdominal pain and diarrhea usually with hematochezia<span>. Optimal medical management of ulcerative colitis is aimed at resolving clinical symptoms as well as achieving mucosal healing. Treatments are selected based on several variables including severity of symptoms, overall inflammatory burden, and whether risk factors for poor prognosis are present. Various medications currently approved for use in ulcerative colitis include 5-aminosalicylates, corticosteroids, </span></span>thiopurines<span>, anti-tumor necrosis factor antagonists, ustekinumab<span>, vedolizumab, and </span></span></span>tofacitinib. While the appropriate use of these as solitary </span>drugs<span> or in combination is often straightforward, therapy for particularly complex patients such as those requiring a rapid onset of action, those who are elderly or have significant medical co-morbidities, those with history of or active malignancy, those who are pregnant or breastfeeding, as well as those with extra-intestinal manifestations requires special consideration.</span></span></p></div>","PeriodicalId":55956,"journal":{"name":"Seminars in Colon and Rectal Surgery","volume":"33 1","pages":"Article 100863"},"PeriodicalIF":0.4000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medical treatment of ulcerative colitis\",\"authors\":\"Sumona Bhattacharya MD , Raymond K. Cross MD, MS\",\"doi\":\"10.1016/j.scrs.2022.100863\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ulcerative colitis<span><span><span><span> is a chronic inflammatory condition characterized by abdominal pain and diarrhea usually with hematochezia<span>. Optimal medical management of ulcerative colitis is aimed at resolving clinical symptoms as well as achieving mucosal healing. Treatments are selected based on several variables including severity of symptoms, overall inflammatory burden, and whether risk factors for poor prognosis are present. Various medications currently approved for use in ulcerative colitis include 5-aminosalicylates, corticosteroids, </span></span>thiopurines<span>, anti-tumor necrosis factor antagonists, ustekinumab<span>, vedolizumab, and </span></span></span>tofacitinib. While the appropriate use of these as solitary </span>drugs<span> or in combination is often straightforward, therapy for particularly complex patients such as those requiring a rapid onset of action, those who are elderly or have significant medical co-morbidities, those with history of or active malignancy, those who are pregnant or breastfeeding, as well as those with extra-intestinal manifestations requires special consideration.</span></span></p></div>\",\"PeriodicalId\":55956,\"journal\":{\"name\":\"Seminars in Colon and Rectal Surgery\",\"volume\":\"33 1\",\"pages\":\"Article 100863\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Colon and Rectal Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043148922000045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Colon and Rectal Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043148922000045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Ulcerative colitis is a chronic inflammatory condition characterized by abdominal pain and diarrhea usually with hematochezia. Optimal medical management of ulcerative colitis is aimed at resolving clinical symptoms as well as achieving mucosal healing. Treatments are selected based on several variables including severity of symptoms, overall inflammatory burden, and whether risk factors for poor prognosis are present. Various medications currently approved for use in ulcerative colitis include 5-aminosalicylates, corticosteroids, thiopurines, anti-tumor necrosis factor antagonists, ustekinumab, vedolizumab, and tofacitinib. While the appropriate use of these as solitary drugs or in combination is often straightforward, therapy for particularly complex patients such as those requiring a rapid onset of action, those who are elderly or have significant medical co-morbidities, those with history of or active malignancy, those who are pregnant or breastfeeding, as well as those with extra-intestinal manifestations requires special consideration.
期刊介绍:
Seminars in Colon and Rectal Surgery offers a comprehensive and coordinated review of a single, timely topic related to the diagnosis and treatment of proctologic diseases. Each issue is an organized compendium of practical information that serves as a lasting reference for colorectal surgeons, general surgeons, surgeons in training and their colleagues in medicine with an interest in colorectal disorders.